The Scream star — and son of Dennis Quaid and Meg Ryan — also admitted that he didn’t think the group chat would still be ...

In a report released on March 14, Matthew Biegler from Oppenheimer reiterated a Buy rating on Allogene Therapeutics (ALLO – Research Report), ...

Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...

Such an advance, leaders agree, would fundamentally transform society. Google CEO Sundar Pichai has repeatedly described AI ...

Expedia Group (NASDAQ:EXPE – Free Report) had its price objective trimmed by Oppenheimer from $235.00 to $230.00 in a ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Hold rating on Cartesian Therapeutics (RNAC – Research Report). The ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

Netflix’s CCO Bela Bajaria believes Oppenheimer would have thrived on streaming. But would it really match its box office ...

AI, as an immortal intelligence, does not experience death, fear, or existential urgency. This raises profound questions: How ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...

Remembering Pat, a good friend from Omaha, Neb.

Investing.com - Tesla’s ability to replace some of its consumer base driven away by the political activities of CEO Elon Musk will likely influence the near-term performance of the stock, according to ...